Dominique Berton - Concepedia

Author

Dominique Berton

Institut de Cancérologie de l'Ouest

Also Known As

D Berton, D. Berton, DOMINIQUE BERTON, Dominique Berton, F. Bazan

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Institut de Cancérologie de l'Ouest Centre Léon Bérard Institut Gustave Roussy Institut Claudius Regaud Centre Oscar Lambret

About

Dominique Berton is an author at Institut de Cancérologie de l'Ouest specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	743
2	Immunology	3	3	173
3	Health Sciences	2	2	108
4	Cell Biology	1	1	16
5	Molecular Medicine	1	1	11

Dominique Berton

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, The Lancet OncologyCervical CancerMetronomic TherapyPathologyRecurrent Cervical Cancer	2023	175
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal, Annals of Oncology Post-hoc AnalysesMedicineSubsequent ChemotherapyGynecologyCancer Treatment	2022	140
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer David M. O’Malley, Ana Oaknin, Bradley J. Monk, Gynecologic Oncology	2021	127
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors Thierry André, Dominique Berton, Giuseppe Curigliano, JAMA Network Open	2023	103
Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. Thierry André, Dominique Berton, Giuseppe Curigliano, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsImmunotherapyOncology	2021	96
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer Ursula A. Matulonis, Jørn Herrstedt, Amit M. Oza, Gynecologic Oncology MedicineCancer ManagementGynecologyRecurrent Ovarian CancerSecondary Efficacy Endpoints	2021	60
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Philipp Harter, International Journal of Gynecological Cancer	2023	51
Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. Dominique Berton, Susana Banerjee, Giuseppe Curigliano, Journal of Clinical Oncology Antitumor ActivityDmmr Solid TumorsCancer ManagementImmunologyPathology	2021	40
LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials David M. O’Malley, Ana Oaknin, Bradley J. Monk, Annals of Oncology Cervical CancerMedicineImmunologyAnti-ctla-4 ZalifrelimabPathology	2020	37
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, Gynecologic Oncology Local TherapyMedicineMetronomic TherapyGynecologyParp Inhibitors	2023	32

Page 1